Research
Hormonal
Daily oral administration of live Akkermansia muciniphila (2.10^8 cells) improves metabolic health in high-fat diet-fed mice by restoring gut barrier function and reducing metabolic endotoxemia.
While human trials are ongoing, current research suggests that consuming Akkermansia muciniphila (specifically pasteurized forms which are more stable and effective) may help improve metabolic health by strengthening the gut barrier. It is not just about 'live' bacteria; the structural components of the bacteria are key.
ModerateSupportsMEDIUM confidence
We found that the administration of live A. muciniphila at the dose of 2.108 bacterial cells per day was partly protecting against diet-induced obesity in mice... This protection was mirrored by two times less visceral and subcutaneous fat mass... animals receiving live A. muciniphila did no longer exhibited insulin resistance... live A. muciniphila prevented the development of metabolic endotoxemia, an effect associated with the restoration of a normal mucus layer thickness
Why this rating
Strong preclinical evidence in mice; limited human safety data (20 subjects) but no efficacy data yet.
Source
Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila
Patrice D. Cani et al. · Frontiers in Microbiology · 2017
DOI 10.3389/fmicb.2017.01765
narrative_reviewCited 1,058×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- A specific outer membrane protein from Akkermansia muciniphila, Amuc_1100, mediates the metabolic benefits by activating Toll-Like Receptor 2 (TLR2).Good
- Pasteurization of Akkermansia muciniphila enhances its metabolic benefits compared to live administration, likely due to the exposure of outer membrane proteins like Amuc_1100.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →